Ipsen loses a quarter of value based on pause of palovarotene trials
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Ipsen reports data from pancreatic ductal adenocarcinoma trial
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen on LinkedIn: Ipsen announces positive clinical trial findings in patients living with… | 23 comments
Ipsen gets U.S. manufacturing with $1.25B deal for Merrimack Pharmaceuticals | Fierce Pharma
Ipsen to acquire worldwide rights to pre-clinical stage oncology programme - PMLiVE
End of Ipsen clinical trial at 177lu-OPS201 - Arronax Nantes
Clinical trials - Ipsen
FDA hits Ipsen's $1B drug with clinical hold over safety signal | Fierce Biotech
Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease - MedCity News
Ipsen finalizes purchase of Albireo Pharma to strengthen its rare disease portfolio | HealthCare Middle East & Africa Magazine
Clinical Trial Associate job with Ipsen Biopharmaceuticals, Inc. | 2725115
PATIENT CENTRICITY IN ACTION
Is Ipsen late reporting EU clinical trials?
Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
Clinical trials - Ipsen
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy | Business Wire
Ipsen receives CRL for potential bone treatment
How the FDA Stifles New Cures, Part II: 90% of Clinical Trial Costs are Incurred in Phase III
Ipsen Becomes First to Best Standard of Care in Metastatic PDAC | BioSpace
Ipsen's rare disease drug palovarotene knocked back in EU | pharmaphorum
